Anlotinib plus sintilimab in patients with recurrent advanced endometrial cancer: A prospective open-label, single-arm, phase II clinical trial.

Wei Wei(Zhujiang Hospital), Min Zheng(Second Affiliated Hospital of Zhejiang University), Xiaohua Ban(Sun Yat-sen University), Fan Yang(Sun Yat-sen University), Yongwen Huang(Sun Yat-sen University), Ya Qiu(Sun Yat-sen University), Jibin Li(State Key Laboratory of Pollution Control and Resource Reuse), Xiaqin Cheng(Sun Yat-sen University), Jundong Li(University of Virginia)
Journal of Clinical Oncology
May 20, 2021
10.1200/jco.2021.39.15_suppl.5583
Cited by 2

Related Papers

Feature Selection
|ACM Computing Surveys|2017|2.3k
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion
|JAMA Oncology|2019|559
Line Graph Neural Networks for Link Prediction
|IEEE Transactions on Pattern Analysis and Machine Intelligence|2021|235
Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment
|JAMA|2020|229
Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial
|Journal of Clinical Oncology|2020|217